Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $26.4 million.

  • Iovance Biotherapeutics' Net Cash Flow rose 140.06% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year increase of 96.50%. This contributed to the annual value of -$58.7 million for FY2024, which is 8.58% down from last year.
  • Iovance Biotherapeutics' Net Cash Flow amounted to $26.4 million in Q3 2025, which was up 165.31% from -$40.4 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Net Cash Flow peaked at $311.8 million during Q1 2023, and registered a low of -$249.7 million during Q2 2023.
  • Its 3-year average for Net Cash Flow is -$6.5 million, with a median of -$40.2 million in 2024.
  • In the last 5 years, Iovance Biotherapeutics' Net Cash Flow slumped by 265.78% in 2024 and then spiked by 237.98% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Net Cash Flow (Quarterly) stood at -$155.9 million in 2023, then soared by 69.63% to -$47.3 million in 2024, then spiked by 140.06% to $26.4 million in 2025.
  • Its last three reported values are $26.4 million in Q3 2025, -$40.4 million for Q2 2025, and $55.5 million during Q1 2025.